Rocket Pharma officer sells 3,726 RCKT shares

Rocket Pharmaceuticals officer John Militello reported an open-market sale of 3,726 shares of common stock at $3.312 per share.

Accepted by SEC EDGAR 02/18/2026 - 05:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Rocket Pharmaceuticals officer John Militello reported an open-market sale of 3,726 shares of common stock at $3.312 per share. According to the footnotes, the sale was made to cover tax withholding obligations from vested restricted stock units, and Militello now holds 92,176 shares, including RSUs that convert to common stock on a one-for-one basis.

Insider Trade Summary

Net Seller: 3,726 shares

Net Sell 1 txn

Insider Militello John

Role See Remarks

Sold 3,726 shs ($12K)

Share of Position Sold 3.9%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,726	$3.312	$12K

Holdings After Transaction: Common Stock — 92,176 shares (Direct)

Holdings Before and After: Common Stock, 95,902 to 92,176 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. F2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RCKT officer John Militello report?

John Militello reported selling 3,726 Rocket Pharmaceuticals shares in an open-market transaction. The shares were sold at $3.312 each to cover tax withholding obligations tied to vested restricted stock units, according to the filing footnotes.

Why did the Rocket Pharmaceuticals (RCKT) insider sell 3,726 shares?

The 3,726 Rocket Pharmaceuticals shares were sold to satisfy tax withholding obligations from the vesting of restricted stock units. The filing specifies this tax-related purpose, indicating the transaction was not a discretionary share sale for portfolio rebalancing or liquidity needs.

What price did the RCKT insider receive per share in the reported sale?

The Rocket Pharmaceuticals officer received $3.312 per share for the 3,726 shares sold. This price reflects the open-market transaction value disclosed in the Form 4 and is directly tied to covering tax obligations from RSU vesting.

How many Rocket Pharmaceuticals (RCKT) shares does the insider hold after the sale?

After the sale, the officer beneficially owns 92,176 Rocket Pharmaceuticals shares. This total includes restricted stock units that convert into common stock on a one-for-one basis, as noted in the footnotes to the insider transaction filing.

Does the RCKT insider’s holding include restricted stock units (RSUs)?

Yes, the reported 92,176 Rocket Pharmaceuticals shares include restricted stock units. The filing explains these RSUs convert to common stock on a one-for-one basis, meaning each unit will become a single share when it vests and settles.

Is the Rocket Pharmaceuticals insider sale characterized as a routine tax withholding event?

Yes, the filing states the shares were sold to pay tax withholding obligations related to RSU vesting. This language indicates the sale functions as a tax-related event rather than a discretionary reduction of the insider’s overall economic exposure to Rocket Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Militello John

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/13/2026		S(2)		3,726	D	$3.312	92,176(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Remarks:

Vice President of Finance, Treasurer, Principal Accounting Officer

	/s/ Martin Wilson, as attorney-in-fact for John Militello	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.